Treatment of Mild to Moderate Pulmonary Blastomycosis in Immunocompetent Adults (Age 18+)

Clinical Scenario

This protocol covers mild to moderate acute pulmonary blastomycosis in an immunocompetent adult aged 18 years or older who is not immunosuppressed. In this population, the disease can follow a mild, self-limited course — but the decision to treat and the choice of therapy require careful clinical evaluation.

Patient Profile

The defining characteristics of this scenario are age 18 or older, pulmonary involvement that is mild to moderate in severity, and an intact immune system with no immunosuppression. These factors directly shape the treatment approach outlined in the full protocol.

Treatment Approach

When antifungal treatment is indicated in this setting, the protocol specifies oral antifungal therapy as the therapeutic approach — including consideration of alternative agents for patients with specific tolerability or drug-interaction constraints. The complete agent selection criteria, sequencing, and course details are in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1086/588300

In the immunocompetent host, acute pulmonary blastomycosis can be mild and self-limited and may not require treatment.

Alternatives for those patients who are unable to tolerate itraconazole or who are unable to take this agent because of drug-drug interactions or failure to absorb the drug include ketoconazole (at a dosage of 400–800 mg per day) or fluconazole (at a dosage of 400–800 mg per day), but these alternatives are less effective, and the toxicity of ketoconazole is greater than that of the other agents.

View source ↗